Small Cell Lung Cancer, Version 2.2022
Small Cell Lung Cancer, Version 2.2022
复制标题
DOI：
10.6004/jnccn.2021.0058
复制
发表时间：
2021-12-01
影响因子：
13.4
通讯作者：
Hughes, Miranda
中科院分区：
文献类型：
--
作者：
Ganti, Apar Kishor P.;Loo, Billy W.;Hughes, Miranda
NCCN肿瘤临床实践指南(NCCN指南)为小细胞肺癌(SCLC)患者提供了建议的治疗方法，包括诊断、初步治疗、复发监测和后续治疗。这本杂志的选择集中在转移性(即广泛期)小细胞肺癌，它比有限分期的小细胞肺癌更常见。在大多数广泛期疾病的患者中，仅系统治疗就可以缓解症状并延长生存时间。在小细胞肺癌和其他高级别神经内分泌癌患者中，应大力提倡戒烟咨询和干预。SCLC算法中的“准则更新摘要”部分概述了2022年更新的最新修订，在这一修订后的讨论文本中有更详细的描述。
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.